研究二甲双胍对2型糖尿病患者COVID-19严重程度的影响:以实验室结果为重点

IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM Endocrinology, Diabetes and Metabolism Pub Date : 2023-07-11 DOI:10.1002/edm2.441

Rana Taheri, Seyedeh Zahra Shahrokhi, Zahra Amjadi, Faranak Kazerouni

{"title":"研究二甲双胍对2型糖尿病患者COVID-19严重程度的影响:以实验室结果为重点","authors":"Rana Taheri, Seyedeh Zahra Shahrokhi, Zahra Amjadi, Faranak Kazerouni","doi":"10.1002/edm2.441","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>In the terrifying pandemic caused by SARS-CoV-2, diabetic patients exhibiting more severe outcomes and mortality rate is high among them. Based on recent studies, metformin as the most prescribed drug for T2DM treatment may improve severe outcomes in diabetic patients infected with SARS-CoV-2. On the other hand, abnormal laboratory findings can help to differentiate between the severe and non-severe form of COVID-19. According to the mentioned issues, the effect of metformin on severity of COVID-19 was examined in T2DM patients with SARS-CoV-2 infection.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The study included 187 individuals diagnosed with COVID-19, 104 patients were diabetic and divided into two groups according to their anti-diabetic drugs: patients who were treated only with metformin and patients who were treated with other anti-diabetic drugs. The other participants were non-diabetic and diagnosed with COVID-19. Biochemical parameters were measured by routine laboratory methods before, during and after SARS-CoV-2 infection.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>During infection, FBS, creatinine, ALT, AST, Ferritin and LDH were significantly lower in metformin users than non-users (<i>p</i>-<i>value</i>: .02, .01, .03, .04, .0009 and .01, respectively). Also, after recovery, there were statistically significant differences between metformin users and non-users with respect to most of the study parameters, except FBS, BUN and ALP (<i>p-value</i>: .51, .28 and .35, respectively).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our result suggested that metformin might be associated with better outcomes in diabetic patients infected with SARS-CoV-2.</p>\n </section>\n </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"6 5","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.441","citationCount":"0","resultStr":"{\"title\":\"Investigating the impact of metformin on severity of COVID-19 in patients with Type 2 diabetes mellitus: Focusing on laboratory findings\",\"authors\":\"Rana Taheri, Seyedeh Zahra Shahrokhi, Zahra Amjadi, Faranak Kazerouni\",\"doi\":\"10.1002/edm2.441\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>In the terrifying pandemic caused by SARS-CoV-2, diabetic patients exhibiting more severe outcomes and mortality rate is high among them. Based on recent studies, metformin as the most prescribed drug for T2DM treatment may improve severe outcomes in diabetic patients infected with SARS-CoV-2. On the other hand, abnormal laboratory findings can help to differentiate between the severe and non-severe form of COVID-19. According to the mentioned issues, the effect of metformin on severity of COVID-19 was examined in T2DM patients with SARS-CoV-2 infection.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>The study included 187 individuals diagnosed with COVID-19, 104 patients were diabetic and divided into two groups according to their anti-diabetic drugs: patients who were treated only with metformin and patients who were treated with other anti-diabetic drugs. The other participants were non-diabetic and diagnosed with COVID-19. Biochemical parameters were measured by routine laboratory methods before, during and after SARS-CoV-2 infection.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>During infection, FBS, creatinine, ALT, AST, Ferritin and LDH were significantly lower in metformin users than non-users (<i>p</i>-<i>value</i>: .02, .01, .03, .04, .0009 and .01, respectively). Also, after recovery, there were statistically significant differences between metformin users and non-users with respect to most of the study parameters, except FBS, BUN and ALP (<i>p-value</i>: .51, .28 and .35, respectively).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Our result suggested that metformin might be associated with better outcomes in diabetic patients infected with SARS-CoV-2.</p>\\n </section>\\n </div>\",\"PeriodicalId\":36522,\"journal\":{\"name\":\"Endocrinology, Diabetes and Metabolism\",\"volume\":\"6 5\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2023-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.441\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinology, Diabetes and Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/edm2.441\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology, Diabetes and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/edm2.441","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

在可怕的SARS-CoV-2大流行中，糖尿病患者表现出更严重的后果，其中死亡率很高。根据最近的研究，二甲双胍作为治疗T2DM的最常用药物可能改善感染SARS-CoV-2的糖尿病患者的严重结局。另一方面，异常的实验室检查结果有助于区分COVID-19的严重和非严重形式。根据上述问题，研究了二甲双胍对合并SARS-CoV-2感染的T2DM患者COVID-19严重程度的影响。方法选取187例新冠肺炎确诊患者，其中糖尿病患者104例，根据降糖药的不同分为仅使用二甲双胍组和同时使用其他降糖药组。其他参与者是非糖尿病患者，并被诊断为COVID-19。在SARS-CoV-2感染之前、期间和之后，采用常规实验室方法测量生化参数。结果感染期间，二甲双胍服用者FBS、肌酐、ALT、AST、铁蛋白和LDH均显著低于非服用者(p值分别为0.02、0.01、0.03、0.04、0.09和0.01)。恢复后，除FBS、BUN、ALP外，二甲双胍服用者与非服用者在大多数研究参数上差异均有统计学意义(p值分别为0.51、0.28、0.35)。结论二甲双胍可能与感染SARS-CoV-2的糖尿病患者预后较好相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Investigating the impact of metformin on severity of COVID-19 in patients with Type 2 diabetes mellitus: Focusing on laboratory findings

Background

In the terrifying pandemic caused by SARS-CoV-2, diabetic patients exhibiting more severe outcomes and mortality rate is high among them. Based on recent studies, metformin as the most prescribed drug for T2DM treatment may improve severe outcomes in diabetic patients infected with SARS-CoV-2. On the other hand, abnormal laboratory findings can help to differentiate between the severe and non-severe form of COVID-19. According to the mentioned issues, the effect of metformin on severity of COVID-19 was examined in T2DM patients with SARS-CoV-2 infection.

Methods

The study included 187 individuals diagnosed with COVID-19, 104 patients were diabetic and divided into two groups according to their anti-diabetic drugs: patients who were treated only with metformin and patients who were treated with other anti-diabetic drugs. The other participants were non-diabetic and diagnosed with COVID-19. Biochemical parameters were measured by routine laboratory methods before, during and after SARS-CoV-2 infection.

Results

During infection, FBS, creatinine, ALT, AST, Ferritin and LDH were significantly lower in metformin users than non-users (p-value: .02, .01, .03, .04, .0009 and .01, respectively). Also, after recovery, there were statistically significant differences between metformin users and non-users with respect to most of the study parameters, except FBS, BUN and ALP (p-value: .51, .28 and .35, respectively).